AU2002243801B2 - Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same - Google Patents

Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same Download PDF

Info

Publication number
AU2002243801B2
AU2002243801B2 AU2002243801A AU2002243801A AU2002243801B2 AU 2002243801 B2 AU2002243801 B2 AU 2002243801B2 AU 2002243801 A AU2002243801 A AU 2002243801A AU 2002243801 A AU2002243801 A AU 2002243801A AU 2002243801 B2 AU2002243801 B2 AU 2002243801B2
Authority
AU
Australia
Prior art keywords
acid
ditpa
patient
diiodothyropropionic
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002243801A
Other languages
English (en)
Other versions
AU2002243801A1 (en
Inventor
Joseph J. Bahl
Steven Goldman
Eugene Morkin
Gregory D. Pennock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona's Public Universities
Original Assignee
University of Arizona
Arizona's Public Universities
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arizona, Arizona's Public Universities filed Critical University of Arizona
Publication of AU2002243801A1 publication Critical patent/AU2002243801A1/en
Application granted granted Critical
Publication of AU2002243801B2 publication Critical patent/AU2002243801B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002243801A 2001-01-31 2002-01-31 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same Ceased AU2002243801B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/774,994 US6534676B2 (en) 2001-01-31 2001-01-31 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
US09/774,994 2001-01-31
PCT/US2002/003162 WO2002060389A2 (en) 2001-01-31 2002-01-31 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same

Publications (2)

Publication Number Publication Date
AU2002243801A1 AU2002243801A1 (en) 2003-02-20
AU2002243801B2 true AU2002243801B2 (en) 2006-12-07

Family

ID=25102976

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002243801A Ceased AU2002243801B2 (en) 2001-01-31 2002-01-31 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same

Country Status (7)

Country Link
US (1) US6534676B2 (enExample)
EP (1) EP1432310A4 (enExample)
JP (1) JP2004522747A (enExample)
AU (1) AU2002243801B2 (enExample)
CA (1) CA2436421C (enExample)
MX (1) MXPA03006855A (enExample)
WO (1) WO2002060389A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716877B2 (en) * 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels
US7504435B2 (en) * 2001-01-31 2009-03-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for stimulating weight loss and/or for lowering triglycerides in patients
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
AU2004273986B2 (en) * 2003-09-15 2010-04-22 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use in angiogenesis
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
EP2428516A1 (en) * 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
CA2583410A1 (en) * 2004-09-15 2006-03-23 Albany College Of Pharmacy Thyroid hormone analogs for promoting angiogenesis
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
EP2120913B1 (en) * 2006-12-22 2015-01-21 NanoPharmaceuticals LLC Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
AU2008219585A1 (en) * 2007-02-27 2008-09-04 The Arizona Board Of Regents On Behalf Of The University Of Arizona Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome.
JPWO2009028608A1 (ja) * 2007-08-31 2010-12-02 三菱瓦斯化学株式会社 オルト位がヨウ素置換されたフェノール誘導体の製造方法
WO2010075332A1 (en) * 2008-12-23 2010-07-01 Charitable Leadership Foundation Small molecule ligands of the integrin rgd recognition site and methods of use
US9180107B2 (en) * 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
WO2010148007A2 (en) 2009-06-17 2010-12-23 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
WO2015120458A1 (en) * 2014-02-10 2015-08-13 Fred Hutchinson Cancer Research Center Halogen treatment of heart attack and ischemic injury
AU2017279536A1 (en) 2016-06-07 2018-12-20 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αvβ3 integrin thyroid antagonists
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
JP2025522112A (ja) 2022-07-11 2025-07-10 プリズム・エルエルシー アラン・ハーンドン・ダドリー症候群を治療するための方法
CA3261860A1 (en) * 2022-07-11 2024-01-18 Dexcel Pharma Technologies Ltd. METHODS AND FORMULATIONS FOR THE PRENATAL TREATMENT OF ALLAN-HERNDON-DUDLEY SYNDROME
WO2024015764A1 (en) * 2022-07-11 2024-01-18 PriZm, LLC 3,5-diiodothyropropionic acid compositions and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US812140A (en) * 1901-06-14 1906-02-06 Perry E Kent Gun-barrel for pistols, rifles, and ordnance.
US2803654A (en) 1955-06-24 1957-08-20 Baxter Laboratories Inc Preparation of thyroxine products
DE1078582B (de) * 1958-10-29 1960-03-31 Hoechst Ag Verfahren zur Herstellung substituierter Thyropropionsaeuren
US3102136A (en) * 1959-06-24 1963-08-27 Warner Lambert Pharmaceutical Process of preparing diiodinated analogs of thyronine
US3149153A (en) * 1961-12-05 1964-09-15 Smith Kline French Lab 3'-substituted-3, 5-diiodothyronine and salts thereof
US5158978A (en) 1990-02-05 1992-10-27 British Technology Group (U.S.A.) Thyroid hormone treatment of acute cardiovascular compromise
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
WO1993017680A1 (en) * 1992-03-13 1993-09-16 Sepracor, Inc. Antipyretic and analgesic methods and compositions containing optically pure r-etodolac
US5284971A (en) 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs

Also Published As

Publication number Publication date
EP1432310A2 (en) 2004-06-30
CA2436421C (en) 2011-06-14
CA2436421A1 (en) 2002-08-08
EP1432310A4 (en) 2006-06-21
US6534676B2 (en) 2003-03-18
US20020151594A1 (en) 2002-10-17
MXPA03006855A (es) 2004-03-12
WO2002060389A3 (en) 2004-04-15
WO2002060389A2 (en) 2002-08-08
JP2004522747A (ja) 2004-07-29

Similar Documents

Publication Publication Date Title
CA2436421C (en) Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
AU2002243801A1 (en) Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
KR910004572B1 (ko) 경구용 당뇨병 치료제 제형의 제조방법
Yau et al. Vitamin E for coronary bypass operations: a prospective, double-blind, randomized trial
Casale et al. Simultaneous low level treadmill exercise and intravenous dipyridamole stress thallium imaging
JP3631755B2 (ja) ポリオキシエチレン含有脂質二本鎖誘導体
US8071125B2 (en) Transdermal patch containing isosorbide dinitrate and bisoprolol
AU2003286546B2 (en) Method to treat chronic heart failure and/or elevated cholesterol levels
Shen et al. Microenvironment responsive nanoplatform for targeted removal of cholesterol and reshaping inflammatory microenvironment in atherosclerotic plaques
Liu et al. Combining ion-pair strategy and chemical enhancers to develop mirtazapine long-acting transdermal patches for depression treatment
PL183104B1 (pl) Kompozycja liposomowa i kompozycja farmaceutyczna
US6998422B2 (en) Lipid peroxide-lowering compositions
US11590240B2 (en) Nano-fibular nanoparticle polymer-drug conjugate for sustained dermal delivery of retinoids
US20050159490A1 (en) Method to treat chronic heart failure and/or elevated cholesterol levels
WO2014086819A1 (en) Methods and pharmaceutical composition for the treatment and prevention of cardiac arrhythmias
CN118526498B (zh) 9-o-丁二酸单乙酯小檗红碱衍生物在制备治疗心脏纤维化的药物中的应用
CN107823649B (zh) 一种丹皮酚-奥扎格雷偶联物脑靶向脂质体及其制备方法
EP2397129A1 (en) Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
JP2002503209A (ja) 著しく改善された抗腫瘍活性によるリポソーム抗腫瘍療法
US6673785B1 (en) Use of hepoxilins or hepoxilin analogs as antidiabetics, antiinflammatory agents
Leclercq et al. Flecainide acetate dose-concentration relationship in cardiac arrhythmias: influence of heart failure and amiodarone
CN112823793A (zh) 一种含有多奈哌齐的透皮贴剂及其制备方法
JPH01228920A (ja) 吸収促進剤
JP2000511526A (ja) 血栓症の処置のための新規改良組成物
WO2026002967A1 (en) Leoligin and derivatives thereof as calcium channel blockers for the prevention and/or treatment of related diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired